Hong-Shuo Sun Selected Research

xyloketal B

1/2022	Xyloketal B: A marine compound with medicinal potential.
12/2018	Marine Compound Xyloketal B as a Potential Drug Development Target for Neuroprotection.
9/2017	Xyloketal B alleviates cerebral infarction and neurologic deficits in a mouse stroke model by suppressing the ROS/TLR4/NF-κB inflammatory signaling pathway.
4/2015	Xyloketal B suppresses glioblastoma cell proliferation and migration in vitro through inhibiting TRPM7-regulated PI3K/Akt and MEK/ERK signaling pathways.
4/2015	Xyloketal B attenuates atherosclerotic plaque formation and endothelial dysfunction in apolipoprotein e deficient mice.
12/2014	Marine compound xyloketal B reduces neonatal hypoxic-ischemic brain injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hong-Shuo Sun Research Topics

Disease

15	Ischemia 01/2021 - 04/2006
14	Brain Injuries (Brain Injury) 08/2022 - 12/2014
13	Stroke (Strokes) 05/2022 - 09/2008
9	Hypoxia (Hypoxemia) 05/2018 - 01/2007
7	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 04/2015
7	Ischemic Stroke 01/2021 - 01/2018
6	Inflammation (Inflammations) 04/2022 - 01/2018
5	Infarction (Infarctions) 01/2022 - 12/2014
4	Brain Ischemia (Cerebral Ischemia) 01/2021 - 04/2006
3	Glioma (Gliomas) 04/2022 - 01/2019
3	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 09/2017 - 04/2006
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 10/2016
2	Neoplasms (Cancer) 01/2021 - 10/2020
2	Body Weight (Weight, Body) 12/2019 - 01/2017
2	Cognitive Dysfunction 08/2019 - 04/2019
2	Cerebral Infarction 09/2017 - 10/2016
2	Type 2 Diabetes Mellitus (MODY) 01/2017 - 01/2016
2	Brain Infarction 10/2016 - 02/2015
2	Cicatrix (Scar) 01/2008 - 11/2007
1	Parkinson Disease (Parkinson's Disease) 03/2022
1	Non-alcoholic Fatty Liver Disease 01/2022
1	Vascular Remodeling 01/2022
1	Pathologic Processes 01/2021
1	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2021
1	Vision Disorders (Hemeralopia) 01/2021
1	Central Nervous System Diseases (CNS Diseases) 12/2020
1	Brain Edema (Cerebral Edema) 10/2020
1	Necrosis 10/2020
1	Lipid Metabolism Disorders (Metabolism Disorders, Lipid) 12/2019
1	Obesity 12/2019
1	Cerebral Small Vessel Diseases 08/2019
1	Williams Syndrome (Williams-Beuren Syndrome) 05/2019
1	Neurodevelopmental Disorders 05/2019
1	Myotoxicity 04/2019
1	Muscular Diseases (Myopathy) 04/2019
1	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 04/2019
1	Brain Hypoxia-Ischemia (Hypoxia Ischemia, Brain) 05/2018

Drug/Important Bio-Agent (IBA)

12	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2007
10	Pharmaceutical PreparationsIBA 04/2022 - 02/2015
8	Glucose (Dextrose)FDA LinkGeneric 08/2022 - 04/2006
8	Neuroprotective AgentsIBA 01/2022 - 01/2016
6	Oxygen (Dioxygen)IBA 08/2022 - 04/2006
6	xyloketal BIBA 01/2022 - 12/2014
4	ChloridesIBA 05/2018 - 11/2007
3	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 04/2022 - 09/2007
3	Ion Channels (Ion Channel)IBA 04/2022 - 05/2018
3	carvacrolIBA 01/2022 - 02/2015
3	waixenicin AIBA 01/2021 - 12/2020
3	Chloride Channels (Chloride Channel)IBA 10/2020 - 10/2016
3	Biomarkers (Surrogate Marker)IBA 10/2020 - 01/2018
3	Streptozocin (Streptozotocin)FDA Link 01/2017 - 10/2004
2	alpha- cyano- (3,4- dihydroxy)- N- benzylcinnamideIBA 03/2022 - 12/2019
2	CationsIBA 01/2021 - 12/2019
2	oxidized low density lipoproteinIBA 08/2019 - 01/2018
2	KATP ChannelsIBA 05/2018 - 01/2016
2	RNA (Ribonucleic Acid)IBA 01/2018 - 01/2008
2	Adenosine Triphosphate (ATP)IBA 01/2016 - 01/2015
2	Therapeutic UsesIBA 04/2015 - 01/2015
2	Qa-SNARE Proteins (Syntaxin)IBA 01/2008 - 01/2007
2	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 01/2008 - 11/2007
2	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 01/2008 - 01/2007
1	ChemokinesIBA 05/2022
1	Focal Adhesion Kinase 2IBA 04/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2022
1	LipidsIBA 01/2022
1	Dantrolene (Dantrium)FDA LinkGeneric 01/2022
1	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 01/2022
1	Becaplermin (PDGF-BB)FDA Link 01/2022
1	CalcineurinIBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	Retinaldehyde (Retinal)IBA 01/2021
1	Calcium-Calmodulin-Dependent Protein KinasesIBA 01/2021
1	CytokinesIBA 01/2021
1	InflammasomesIBA 01/2021
1	Isoflurane FDA LinkGeneric 01/2021
1	quinone (benzoquinone)IBA 10/2020
1	Oxidoreductases (Dehydrogenase)IBA 10/2020
1	Protons (Proton)IBA 10/2020
1	NAD (NADH)IBA 10/2020
1	Aquaporins (Water Channels)IBA 10/2020
1	Amyloid beta-PeptidesIBA 01/2020
1	Long Noncoding RNAIBA 01/2020
1	CalciumIBA 12/2019
1	Superoxide DismutaseIBA 08/2019
1	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 08/2019
1	claulansine FIBA 04/2019
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 04/2019
1	AntioxidantsIBA 04/2019
1	N-desmethyl rosuvastatinIBA 04/2019
1	rosuvastatin lactoneIBA 04/2019
1	Rosuvastatin Calcium (Crestor)FDA Link 04/2019
1	BestrophinsIBA 01/2019
1	multidrug resistance-associated protein 1IBA 01/2019
1	AnionsIBA 01/2019
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 06/2018
1	Hypoglycemic Agents (Hypoglycemics)IBA 05/2018

Therapy/Procedure

2	Ligation 05/2017 - 10/2016
2	Transplantation 01/2008 - 11/2007
1	Drug Therapy (Chemotherapy) 01/2019
1	Therapeutics 05/2018